New therapeutic strategy of fludarabine-resistant relapsed and refractory chronic lymphocytic leukemia

Li hua Qiu, Hua qing Wang

    Research output: Contribution to journalReview article

    Abstract

    Chronic lymphocytic leukemia (CLL) remains an incurable disease. Rituximab and fludarabine are two of the most effective agents in CLL update. Despite the widespread use of highly effective chemoimmunotherapy, fludarabine-refractory CLL remains a challenging problem associated with poor overall survival. Approved therapeutic options for these patients remain limited. Fortunately, allogenetic stem cell transplantation (allo-SCT) and several novel targeted therapeutics in clinical trails hold promise of significant benefit for these patients' population. This review discusses the activity of available and novel targeted therapeutics besides allo-SCT in fludarabine-refractory or fludarabine-resistant CLL.

    Original languageEnglish (US)
    Pages (from-to)520-523
    Number of pages4
    JournalJournal of Leukemia and Lymphoma
    Volume22
    Issue number9
    DOIs
    StatePublished - Sep 1 2013

      Fingerprint

    Keywords

    • Chronic
    • Leukemia
    • Lymphocytic
    • Refractory
    • Relapsed
    • Therapy

    ASJC Scopus subject areas

    • Hematology
    • Oncology
    • Cancer Research

    Cite this